Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364341 | 0.90 | MAP3K5 (0.38) | ESR2TAS2R8MAP3K5NR1H2HDAC6 | |
| SCHEMBL20364363 | 0.89 | ESR2 (0.48) | ESR2TAS2R8MAP3K5NR1H2HDAC6 | |
| SCHEMBL20364335 | 0.89 | MAP3K5 (0.38) | ESR2TAS2R8MAP3K5NR1H2GRAMD1A | |
| SCHEMBL20364342 | 0.89 | MAP3K5 (0.53) | MAP3K5 | |
| SCHEMBL20364343 | 0.88 | MAP3K5 (0.46) | ESR2MAP3K5NR1H2 | |
| SCHEMBL20364353 | 0.87 | MAP3K5 (0.42) | ESR2TAS2R8MAP3K5NR1H2HDAC6 | |
| SCHEMBL20364336 | 0.87 | MAP3K5 (0.40) | ESR2TAS2R8MAP3K5NR1H2GRAMD1A | |
| SCHEMBL20364364 | 0.86 | ESR2 (0.53) | ESR2TAS2R8MAP3K5NR1H2HDAC6 | |
| SCHEMBL20364347 | 0.86 | TAS2R8 (0.49) | ESR2TAS2R8MAP3K5NR1H2HDAC6 | |
| SCHEMBL20169940 | 0.86 | HDAC1 (0.51) | ESR2TAS2R8MAP3K5NR1H2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ESR2 620/4885TAS2R8 2479/4885MAP3K5 3026/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ESR2 620/4885TAS2R8 2479/4885MAP3K5 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.